We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$33.6M
Cap. Flow
+$4.33M
Cap. Flow %
3.64%
Top 10 Hldgs %
74.7%
Holding
51
New
6
Increased
12
Reduced
5
Closed
18

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.09M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.05M
3
PFE icon
Pfizer
PFE
+$1.5M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$1.35M
5
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$1.29M

Top Sells

Rank Stock Value
1
QLTI
QLT Inc
QLTI
+$3.48M
2
HNT
HEALTH NET INC
HNT
+$3.4M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$951K
4
BAX icon
Baxter International
BAX
+$736K
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$570K

Sector Composition

Rank Sector Weight
1 Miscellaneous 52.77%
2 Healthcare 47.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
$19.6M 16.41%
100,000
– –
TWM icon
2
CALL
ProShares UltraShort Russell2000
TWM
$43.9M
$12.9M 10.82%
15,000
+2,500
+20% +$2.38M
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$81.9B
$11.9M 9.96%
100,000
+50,000
+100% +$5.68M
AMRI
4
DELISTED
Albany Molecular Research Inc
AMRI
$10M 8.41%
498,200
+50,000
+11% +$847K
AZN icon
5
AstraZeneca
AZN
$255B
$7.43M 6.23%
100,000
+42,761
+75% +$3.09M
ANIP icon
6
ANI Pharmaceuticals
ANIP
$1.69B
$6.85M 5.75%
199,000
+65,442
+49% +$2.05M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$43.8B
$6.82M 5.72%
130,000
– –
AUXL
8
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$4.6M 3.86%
229,481
+50,000
+28% +$1.15M
DGX icon
9
Quest Diagnostics
DGX
$27B
$4.53M 3.8%
77,208
– –
MRK icon
10
Merck
MRK
$369B
$4.45M 3.74%
80,696
– –
PFE icon
11
Pfizer
PFE
$160B
$4.45M 3.73%
158,100
+52,700
+50% +$1.5M
SNY icon
12
Sanofi
SNY
$107B
$3.07M 2.57%
57,735
– –
BIS icon
13
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$2.85M 2.39%
+5,000
New +$3.44M
BIS icon
14
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$2.85M 2.39%
5,000
+1,875
+60% +$1.29M
SUPN icon
15
CALL
Supernus Pharmaceuticals
SUPN
$2.57B
$2.19M 1.84%
200,000
– –
AMRI
16
CALL
DELISTED
Albany Molecular Research Inc
AMRI
$2.01M 1.69%
100,000
– –
AUXL
17
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$2.01M 1.68%
100,000
-200,000
-67% -$4.59M
IPXL
18
DELISTED
Impax Laboratories, Inc.
IPXL
$1.5M 1.26%
+50,000
New +$1.35M
SRNE
19
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.38M 1.16%
204,968
+104,968
+105% +$792K
TWM icon
20
ProShares UltraShort Russell2000
TWM
$43.9M
$1.08M 0.9%
1,250
– –
VIRX
21
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$978K 0.82%
714
+476
+200% +$552K
KIN
22
DELISTED
Kindred Biosciences, Inc.
KIN
$932K 0.78%
+50,000
New +$849K
SCMP
23
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$667K 0.56%
+96,630
New +$683K
FCSC
24
DELISTED
Fibrocell Science Inc.
FCSC
$629K 0.53%
10,518
+3,333
+46% +$186K
CEMP
25
DELISTED
Cempra, Inc.
CEMP
$537K 0.45%
+50,000
New +$483K
1
2 3

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Healthcare Value Capital held 51 positions worth $119M, down 22% from $153M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Healthcare Value Capital deployed $4.33M of net new capital in Q2 2014, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 53% of assets, down from 65% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Vaxart, an estimated $380K trimmed.

  • Healthcare Value Capital's largest Q2 2014 buy was Impax Laboratories, Inc.: 50,000 shares worth $1.5M.
  • Healthcare Value Capital added most to AstraZeneca in Q2 2014, an estimated $3.09M increase.
  • Healthcare Value Capital's biggest Q2 2014 reduction was Vaxart, cutting an estimated $380K.
  • Healthcare Value Capital fully exited QLT Inc in Q2 2014, selling an estimated $3.48M.
  • Healthcare Value Capital's ten largest holdings make up 75% of its $119M portfolio in Q2 2014.
  • Healthcare Value Capital opened 6 new positions and closed 18 in Q2 2014.
  • Healthcare Value Capital's portfolio value fell 22% quarter-over-quarter to $119M.

Based on Healthcare Value Capital's 13F filing for Q2 2014, filed 13 Aug 2014.